Código QR (código de barras bidimensional)

Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China

Abstract The results of the ETER701 trial showed that benmelstobart and anlotinib plus chemotherapy have potential advantages in the treatment of extensive small cell lung cancer (ES-SCLC). However, it must be noted that the high cost cannot be ignored. This study was designed to assess the cost-eff...

Fuld beskrivelse

Na minha lista:
Principais autores: Chunyan Yan, Zhengxiong Li, Jiayan Li, Quan Zhao, Wenxiu Cao, Shuqing Li, Ruigang Diao
Format: Artigo
Sprog:Inglês
Udgivet: Nature Portfolio 2025-03-01
Serier:Scientific Reports
Fag:
Cost-effectiveness
Benmelstobart
Anlotinib
Extensive-stage small cell lung cancer
Partitioned survival model
First-line
Online adgang:https://doi.org/10.1038/s41598-025-91540-9
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker